Epidemiology of Non-Alcoholic Fatty Liver Disease
The DOI matches its Crossref record; 76 of the 77 references it cites were found in a registry or an index.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is rapidly becoming the most common liver disease worldwide. The prevalence of NAFLD in the general population of Western countries is 20–30%. About 2–3% of the general population is estimated to have non-alcoholic steatohepatitis (NASH), which may progress to liver cirrhosis and hepatocarcinoma. As a rule, the prevalence of NAFLD is higher in males and increases with increasing age, and it is influenced by the diagnostic method and the characteristics of the population, especially lifestyle habits. Population-based studies provide better estimates of the prevalence of NAFLD as compared to autoptic and clinical studies, but few such studies have been performed to date. The diagnosis of NAFLD in population studies is usually obtained by ultrasonography, which is known to underestimate the prevalence of fatty liver. The Dallas Heart Study and the Dionysos Study reported that 30% of the adults in the USA and 25% in Italy have NAFLD. In these studies, 79% and 55% of patients with NAFLD had normal aminotransferase levels, showing that liver enzymes are not surrogate markers of NAFLD in the general population. Noninvasive markers such as the fatty liver index obtained from the Dionysos Study may be useful to screen for NAFLD in the general population. The most important risk factors for NAFLD are male gender, age, obesity, insulin resistance and the cardiometabolic alterations that define the metabolic syndrome. The prevalence of NAFLD is 80–90% in obese adults, 30–50% in patients with diabetes and up to 90% in patients with hyperlipidemia. The prevalence of NAFLD among children is 3–10%, rising up to 40–70% among obese children. Moreover, pediatric NAFLD increased from about 3% a decade ago to 5% today, with a male-to-female ratio of 2:1. The incidence and natural history of NAFLD are still not well defined, but it is recognized that the majority of individuals with NAFLD do not develop NASH. The incidence of NAFLD is probably increasing in Western countries, strictly linked to lifestyle habits.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The prevalence of NAFLD among normal-weight children is 3–10%, rising up to 40–70% among obese children”
From Lack of Exercise Is a Major Cause of Chronic Diseases (2012) · cites this paper as [33]
Citations
Cites
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352 · cited 1×
“In the literature, many competing definitions of the MS are available. The definition recently put forth by the International Federation for the Study of Diabetes (IDF) [”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Prevalence of Hepatic Steatosis in An Urban Population in the United States: Impact of Ethnicity
Browning, J. D., Szczepaniak, L. S., Dobbins, R., Nuremberg, P., Horton, J. D., Cohen, J. C., Grundy, S. M., & Hobbs, H. H. (2004) · Hepatology · doi:10.1002/hep.20466 · Cited by 3,664 · cited 1×
“It is important to note that this prevalence is partly dependent upon the method used to diagnose FL, the method used to assess alcohol intake and the cutoff point used to exclude ‘relevant’ alcohol intake, see table 2 , with respective references [ , , , , , , , , , , , , , , , , , , , , , ,”
MethodNonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345 · cited 1×
“] and 15p in Asian countries [ , , , , , , , , , ,”
Bedogni, G., Bellentani, S., Miglioli, L., Masutti, F., Passalacqua, M., Castiglione, A., & Tiribelli, C. (2006) · BMC Gastroenterology · doi:10.1186/1471-230x-6-33 · Cited by 3,042 · cited 1×
“We suggest to expand the number of prospective cohort studies in the general population, even if they are more expensive and difficult to handle, because they give more reliable results about the burden of disease attributable to NAFLD. The most simple, noninvasive and practical method for diagnosing FL in population…”
BackgroundSelf-citationLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome
Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,679 · cited 1×
“Population and clinical studies have increasingly shown that most cases of NAFLD are associated with the metabolic syndrome (MS), so that NAFLD is presently considered the hepatic manifestation of MS [”
BackgroundNonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154 · cited 1×
“Definition and Classification of Non-Alcoholic Fatty Liver DiseaseNon-alcoholic fatty liver disease (NAFLD) is operationally defined as fatty liver (FL), i.e. an accumulation of lipids inside the hepatocytes exceeding 5p of the weight of the liver, without hepatitis B virus or hepatitis C virus infection and in the ab…”
BackgroundIndependent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis
Angulo, P., Keach, J. C., Batts, K. P., & Lindor, K. D. (1999) · Hepatology · doi:10.1002/hep.510300604 · Cited by 1,610 · cited 1×
“A recent study showed that 27p of US adults have raised levels of liver enzymes and that 79p of these values cannot be explained by the most common causes of liver disease [ , , , , , , , ,”
BackgroundAssociation of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568 · cited 1×
“While steatosis is usually associated with a benign prognosis, steatohepatitis and fibrosis may progress to cirrhosis and possibly hepatocarcinoma.During the last decade, the number of studies on NAFLD has grown exponentially, and new concepts have been acquired by the scientific community. We now know that NAFLD is o…”
Background
Research works printed but not linked: 7
- 10.1097%2f00005176-200001000-00017 · doi:10.1097/00005176-200001000-00017 · Paper page
- 10.1016%2fs1590-8658%2802%2980194-3 · DOI
- 10.1111%2fj.1572-0241.2001.04052.x · doi:10.1111/j.1572-0241.2001.04052.x · Paper page
- 10.1016%2fs0168-8278%2801%2900094-0 · DOI · Paper page
- 10.1111%2fj.1572-0241.1999.01451.x · doi:10.1111/j.1572-0241.1999.01451.x · Paper page
- 10.3109%2f00365527709181339 · DOI · Paper page
- 10.1053%2fgast.2001.25540 · DOI · Paper page
Cited by
Items 101–200 of 1,000
Lean non-alcoholic fatty liver disease
Wang, A. Y., Dhaliwal, J., & Mouzaki, M. (2019) · Clinical Nutrition · doi:10.1016/j.clnu.2018.08.008 · Cited by 120
Norris, G. H., Porter, C. M., Jiang, C., Millar, C. L., & Blesso, C. N. (2016) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2016.09.017 · Cited by 125
Alexander, J., Torbenson, M., Wu, T., & Yeh, M. M. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12116 · Cited by 119
Lipocalin 2 (LCN2) Expression in Hepatic Malfunction and Therapy
Asimakopoulou, A., Weiskirchen, S., & Weiskirchen, R. (2016) · Frontiers in Physiology · doi:10.3389/fphys.2016.00430 · Cited by 116
“Shortly after, an additional investigation demonstrated that LCN2 levels was Frontiers in Physiology | www.frontiersin.org 11 September 2016 | Volume 7 | Article 430 FIGURE 5 | Elevated hepatic LCN2 expression is a physiological indicator of hepatic inflammation.”
BackgroundMilk Polar Lipids: Underappreciated Lipids with Emerging Health Benefits
Anto, L., Warykas, S. W., Torres‐Gonzalez, M., & Blesso, C. N. (2020) · Nutrients · doi:10.3390/nu12041001 · Cited by 128
“In Western societies, it affects 20%–30% of the general population and over 75% of obese individuals [145].”
BackgroundUnraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
Martínez-Uña, M., López-Mancheño, Y., Diéguez, C., Fernández-Rojo, M. A., & Novelle, M. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249368 · Cited by 109
“NAFLD is a disorder defined by excessive fat accumulation in the liver (>5% of hepatocytes histologically) in the form of TG (steatosis) [87,88] and in the absence of excessive alcohol consumption or other known liver pathologies [87,89].”
BackgroundZhang, C., Chen, X., Zhu, R.-M., Zhang, Y., Yu, T., Wang, H., Zhao, H. J., Zhao, M., Ji, Y., Chen, Y., et al. (2012) · Toxicology Letters · doi:10.1016/j.toxlet.2012.06.002 · Cited by 120
Nonalcoholic fatty liver disease: diagnosis and management.
Wilkins, T., Tadkod, A., Hepburn, I. S., & Schade, R. R. (2013) · PubMed · Cited by 138
Nonalcoholic Fatty Liver Disease in Latinos
Saab, S., Manne, V., Nieto, J. M., Schwimmer, J. B., & Chalasani, N. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.05.001 · Cited by 122
Vuppalanchi, R., Jain, A. K., Deppe, R., Yates, K., Comerford, M., Masuoka, H. C., Neuschwander-Tetri, B. A., Loomba, R., Brunt, E. M., Kleiner, D. E., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.05.010 · Cited by 116
“K18 fragment measurement was 29 (14, 58) days at baseline whereas 2 (1, 2) days at week 96.”
BackgroundStandardized Approach for ROI-Based Measurements of Proton Density Fat Fraction and R2* in the Liver
Campo, C. A., Hernando, D., Schubert, T., Bookwalter, C. A., Pay, A. J. V., & Reeder, S. B. (2017) · American Journal of Roentgenology · doi:10.2214/ajr.17.17812 · Cited by 112
Haflidadottir, S., Jonasson, J. G., Norland, H., Einarsdottir, S. O., Kleiner, D. E., Lund, S. H., & Björnsson, E. S. (2014) · BMC Gastroenterology · doi:10.1186/1471-230x-14-166 · Cited by 114
En masse organoid phenotyping informs metabolic-associated genetic susceptibility to NASH
Kimura, M., Iguchi, T., Iwasawa, K., Dunn, A., Thompson, W. L., Yoneyama, Y., Chaturvedi, P., Zorn, A. M., Wintzinger, M., Quattrocelli, M., et al. (2022) · Cell · doi:10.1016/j.cell.2022.09.031 · Cited by 115
Dasarathy, J., Periyalwar, P., Allampati, S., Bhinder, V., Hawkins, C., Brandt, P., Khiyami, A., McCullough, A. J., & Dasarathy, S. (2013) · Liver International · doi:10.1111/liv.12312 · Cited by 116
“As NAFLD has been reported in 20–30% of the Western population (25), the present prospective study was conducted to determine the prevalence of hypovitaminosis D and its relation to body composition in patients with NAFLD compared with controls.”
BackgroundPrevalence and factors associated with nonalcoholic fatty liver disease in shanghai work-units
Hu, X., Huang, Y., Bao, Z., Wang, Y., Shi, D., Liu, F., Gao, Z., & Yu, X. (2012) · BMC Gastroenterology · doi:10.1186/1471-230x-12-123 · Cited by 111
Chen, H., Wang, J., Li, Z., Lam, C. W. K., Xiao, Y., Wu, Q., & Zhang, W. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16122192 · Cited by 112
“The prevalence of NAFLD is estimated to be 20 to 30% in Western countries [4].”
BackgroundThe impact of sex, gender and pregnancy on 2009 H1N1 disease
Klein, S. L., Passaretti, C., Anker, M., Olukoya, '., & Pekosz, A. (2010) · Biology of Sex Differences · doi:10.1186/2042-6410-1-5 · Cited by 113
Al-muzafar, H. M., & Amin, K. A. (2017) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-016-1540-z · Cited by 110
Nonalcoholic Steatohepatitis After Liver Transplantation
Cotter, T. G., & Charlton, M. (2020) · Liver Transplantation · doi:10.1002/lt.25657 · Cited by 109
“(15) Specific evaluation for MS (ie, ≥3 of the following: hypertension, insulin resistance, central obesity, elevated serum triglycerides (TGs), and low high-density lipoprotein [HDL] cholesterol) is mandatory given the high prevalence of MS (36%-63%) in NAFLD patients.(1,16-21) Some conditions also have emerging asso…”
BackgroundInsulin resistance in development and progression of nonalcoholic fatty liver disease
Alam, S., Mustafa, G., Alam, M., & Ahmad, N. (2016) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v7.i2.211 · Cited by 122
Wang, M., Wang, G., Shen, F., Chen, G., Pan, Q., & Fan, J. (2014) · Digestive Diseases and Sciences · doi:10.1007/s10620-014-3180-9 · Cited by 107
Sandboge, S., Perälä, M.-M., Salonen, M. K., Blomstedt, P., Osmond, C., Kajantie, E., Barker, D. J. P., & Eriksson, J. G. (2013) · Annals of Medicine · doi:10.3109/07853890.2013.801275 · Cited by 107
He, X., Gao, J., Hou, H., Qi, Z., Chen, H., & Zhang, X. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.9b05131 · Cited by 111
Alimentary regimen in non-alcoholic fatty liver disease: Mediterranean diet
Abenavoli, L. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i45.16831 · Cited by 103
Tryndyak, V. P., Latendresse, J. R., Montgomery, B., Ross, S. A., Beland, F. A., Rusyn, I., & Pogribny, I. P. (2012) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2012.04.018 · Cited by 106
“The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing dramatically in the United States and developed countries (Tiniakos et al., 2010; Bellentani et al., 2010).”
BackgroundDietary fructose induces endotoxemia and hepatic injury in calorically controlled primates
Kavanagh, K., Wylie, A. T., Tucker, K. L., Hamp, T. J., Gharaibeh, R. Z., Fodor, A. A., & Cullen, J. M. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.112.057331 · Cited by 116
Non-alcoholic fatty liver disease and associated dietary and lifestyle risk factors
Al-Dayyat, H. M., Rayyan, Y. M., & Tayyem, R. (2018) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2018.03.016 · Cited by 115
Deol, P., Evans, J. R., Dhahbi, J., Chellappa, K., Han, D. S., Spindler, S., & Sladek, F. M. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132672 · Cited by 96
Dahlhoff, M., Pfister, S., Blutke, A., Rozman, J., Klingenspor, M., Deutsch, M. J., Rathkolb, B., Fink, B., Gimpfl, M., Hrabě de Angelis, M., et al. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.11.021 · Cited by 100
“Contents lists available at ScienceDirect Biochimica et Biophysica Acta j ourna l homepage: www.e lsev ie r .com/ locate /bbad is Peri-conceptional obesogenic exposure induces sex-specific programming of disease susceptibilities in adult mouse offspring M. Dahlhoff b,1, S. Pfister a,1, A. Blutke c, J. Rozman d,e, M. K…”
BackgroundMachado, M. V., Michelotti, G. A., Pereira, T. D. A., Boursier, J., Kruger, L., Swiderska-Syn, M., Karaca, G., Xie, G., Guy, C. D., Bohinc, B., et al. (2015) · Gut · doi:10.1136/gutjnl-2014-307362 · Cited by 103
Cimini, F. A., Barchetta, I., Carotti, S., Bertoccini, L., Baroni, M. G., Vespasiani-Gentilucci, U., Cavallo, M.-G., & Morini, S. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i19.3407 · Cited by 101
Body Composition in Asians and Caucasians
Haldar, S., Chia, S. C., & Henry, C. J. (2015) · Advances in Food and Nutrition Research · doi:10.1016/bs.afnr.2015.07.001 · Cited by 100
Zhou, Y., Wei, F., & Fan, Y. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.12.010 · Cited by 106
Gawrieh, S., Wilson, L. A., Cummings, O. W., Clark, J. M., Loomba, R., Hameed, B., Abdelmalek, M. F., Dasarathy, S., Neuschwander-Tetri, B. A., Kowdley, K., et al. (2019) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000388 · Cited by 97
Yang, Y. J., Kim, B., Park, Y., Koo, S. I., & Lee, J. (2014) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2014.10.014 · Cited by 110
Jensen, V. S., Hvid, H., Damgaard, J., Nygaard, H., Ingvorsen, C., Wulff, E. M., Lykkesfeldt, J., & Fledelius, C. (2018) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0307-8 · Cited by 109
Tiwari-Heckler, S., Gan-Schreier, H., Stremmel, W., Chamulitrat, W., & Pathil, A. (2018) · Nutrients · doi:10.3390/nu10050649 · Cited by 96
“Non-alcoholic fatty liver disease (NAFLD) is one of the most common causes of chronic liver disease in the western world, and is linked to increasing prevalence of obesity and diabetes [1,2].”
BackgroundGeorge, E. S., Forsyth, A. K., Itsiopoulos, C., Nicoll, A., Ryan, M. C., Sood, S. S., Roberts, S. K., & Tierney, A. C. (2018) · Advances in Nutrition · doi:10.1093/advances/nmx007 · Cited by 102
Rusli, F., Deelen, J., Andriyani, E., Boekschoten, M. V., Lute, C., van den Akker, E. B., Müller, M., Beekman, M., & Steegenga, W. T. (2016) · Scientific Reports · doi:10.1038/srep30484 · Cited by 93
Killeen, M. J., Linder, M., Pontoniere, P., & Crea, R. (2013) · Drug Discovery Today · doi:10.1016/j.drudis.2013.11.002 · Cited by 96
Chemoprevention of nonalcoholic fatty liver disease by dietary natural compounds
Pan, M., Lai, C., Tsai, M., & Ho, C. (2013) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201300522 · Cited by 98
Rho-kinase/AMPK axis regulates hepatic lipogenesis during overnutrition
Hu, H., Lee, S., Sousa‐Lima, I., Kim, S. S., Hwang, W. M., Dagon, Y., Yang, W.-M., Cho, S., Kang, M., Seo, J. A., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci63562 · Cited by 93
Kanerva, N., Sandboge, S., Kaartinen, N. E., Männistö, S., & Eriksson, J. G. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.114.086074 · Cited by 103
Ijssennagger, N., Janssen, A. W. F., Milona, A., Pittol, J. M. R., Hollman, D. A. A., Mokrý, M., Betzel, B., Berends, F. J., Janssen, I. M. C., van Mil, S. W. C., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.01.016 · Cited by 95
Endocrine causes of nonalcoholic fatty liver disease
Marino, L., & Jornayvaz, F. R. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i39.11053 · Cited by 100
Perfield, J. W., Ortinau, L. C., Pickering, R. T., Ruebel, M. L., Meers, G. M., & Rector, R. S. (2013) · Journal of Obesity · doi:10.1155/2013/296537 · Cited by 88
Ji, G., Zhao, X., Leng, L., Liu, P., & Jiang, Z. (2011) · Lipids in Health and Disease · doi:10.1186/1476-511x-10-23 · Cited by 93
Charytoniuk, T., Drygalski, K., Konstantynowicz-Nowicka, K., Berk, K., & Chabowski, A. (2016) · Nutrition · doi:10.1016/j.nut.2016.09.001 · Cited by 96
The metabolic basis of nonalcoholic steatohepatitis
Chakravarthy, M. V., & Neuschwander‐Tetri, B. A. (2020) · Endocrinology, Diabetes & Metabolism · doi:10.1002/edm2.112 · Cited by 87
Obesity-Associated Nonalcoholic Fatty Liver Disease
Yilmaz, Y. N., & Younossi, Z. M. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.09.018 · Cited by 98
“Concomitant with obesity, NAFLD is an increasingly recognized condition; up to 30% of adults in Western countries have NAFLD.33 Insulin resistance is the key pathogenic abnormality associated with obesity-associated NAFLD.34 A fatty liver is insulin resistant and overproduces glucose and very low density lipoprotein,…”
InfluentialRecent Advances in the Herbal Treatment of Non-Alcoholic Fatty Liver Disease
Xiao, J., So, K., Liong, E. C., & Tipoe, G. L. (2013) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.110411 · Cited by 94
Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease
Badmus, O. O., Hinds, T. D., & Stec, D. E. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01242-8 · Cited by 92
Ramírez, A., Vázquez-Sánchez, A. Y., Carrión-Robalino, N., & Camacho, J. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3928714 · Cited by 88
“NASH represents 2–5% of NAFLD cases and is related to increased mortality [106, 107].”
BackgroundAbenavoli, L., Greco, M., Nazionale, I., Peta, V., Milic, N., Accattato, F., Foti, D., Gulletta, E., & Luzza, F. (2015) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2015.1004312 · Cited by 88
“In particular, the favorable effects of the Mediterranean diet on the metabolic syndrome have been demonstrated by several studies [1,2].”
BackgroundFrom the stomach to other organs:Helicobacter pyloriand the liver
Waluga, M., Kukla, M., Żorniak, M., Bacik, A., & Kotulski, R. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i18.2136 · Cited by 96
Noureddin, M., Ntanios, F., Malhotra, D., Hoover, K., Emir, B., McLeod, E., & Alkhouri, N. (2022) · Hepatology Communications · doi:10.1002/hep4.1935 · Cited by 84
Mollard, R. C., Sénéchal, M., MacIntosh, A., Hay, J. L., Wicklow, B. A., Wittmeier, K. D. M., Sellers, E. A. C., Dean, H., Ryner, L. N., Berard, L., et al. (2014) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.079277 · Cited by 94
Buechler, C., Haberl, E., Rein-Fischboeck, L., & Aslanidis, C. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071392 · Cited by 83
“Indeed, chemerin, GPR1 and CMKLR1 knock-out mice do not display gross hepatic abnormalities even when fed diets to produce obesity or NAFLD [93–95].”
BackgroundInfluentialBeneficial effects of noni (Morinda citrifolia L.) juice on livers of high-fat dietary hamsters
Lin, Y., Chang, Y., Yang, D., Tzang, B., & Chen, Y. (2013) · Food Chemistry · doi:10.1016/j.foodchem.2013.02.035 · Cited by 87
Kitamura, H. (2019) · Molecules · doi:10.3390/molecules24234394 · Cited by 101
Martemucci, G., Fracchiolla, G., Muraglia, M., Tardugno, R., Dibenedetto, R. S., & D‘Alessandro, A. G. (2023) · Antioxidants · doi:10.3390/antiox12122091 · Cited by 99
“NAFLD is associated with MS, T2D, obesity and cardiovascular disease [149,151], and affects about 30% of the Western population [152].”
Silva, H. E. D., Arendt, B. M., Noureldin, S. A., Therapondos, G., Guindi, M. M., & Allard, J. P. (2014) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2014.01.009 · Cited by 101
Yang, Y. J., Pham, T. X., Wegner, C., Kim, B., Ku, C. S., Park, Y., & Lee, J. (2014) · British Journal Of Nutrition · doi:10.1017/s0007114514002554 · Cited by 92
“Obesity is also a major risk factor for NAFLD and NASH development((29)).”
BackgroundHagström, H., Stal, P. I., Hultcrantz, R. W., Hemmingsson, T., & Andréasson, A. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.03.019 · Cited by 89
Jump, D. Β., Depner, C. M., Tripathy, S., & Lytle, K. A. (2015) · Advances in Nutrition · doi:10.3945/an.115.009423 · Cited by 92
“NAFLD is the most common fatty liver disease in developed countries (9) and is defined as excessive lipid accumulation in the liver, that is, hepatosteatosis (10, 11).”
BackgroundGenetic and epigenetic variants influencing the development of nonalcoholic fatty liver disease
Li, Y.-Y. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i45.6546 · Cited by 80
Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease
Chen, Y., Xu, M., Wang, T., Sun, J., Sun, W., Xu, B., Huang, X., Xu, Y., Lu, J., Li, X., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.002 · Cited by 91
Association between serum uric acid and nonalcoholic fatty liver disease in the US population
Shih, M., Lazo, M., Liu, S., Bonekamp, S., Hernáez, R., & Clark, J. M. (2013) · Journal of the Formosan Medical Association · doi:10.1016/j.jfma.2012.11.014 · Cited by 92
“12 The associations are robust and occur in a nationally representative sample of the US population for two manifestations of NAFLD: (1) hepatic steatosis; and(2) elevated liver enzymes (AST or ALT), and among different subgroups (by sex, age, and race/ethnicity) as well as the entire population.”
BackgroundMethodCharatcharoenwitthaya, P., Pongpaibul, A., Kaosombatwattana, U., Bhanthumkomol, P., Bandidniyamanon, W., Pausawasdi, N., & Tanwandee, T. (2017) · Liver International · doi:10.1111/liv.13271 · Cited by 82
Mells, J. E., Fu, P. P., Kumar, P., Smith, T., Karpen, S. J., & Anania, F. A. (2015) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2014.11.002 · Cited by 77
“Together, these findings represent increased risk for cirrhosis, clinical end-stage liver disease and hepatocellular carcinoma [3,6,9].”
BackgroundGonciarz, M., Gonciarz, Z., Bielański, W., Mularczyk, A., Konturek, P. C., Brzozowski, T., & Konturek, S. J. (2012) · PubMed · Cited by 97
FAM3 gene family: A promising therapeutical target for NAFLD and type 2 diabetes
Zhang, X., Yang, W., Wang, J., Meng, Y., Guan, Y., & Yang, J. (2017) · Metabolism · doi:10.1016/j.metabol.2017.12.001 · Cited by 85
“The prevalence of NAFLD among children is estimated to be 3% to 10%, and increases to 40% to 70% among obese children [11].”
BackgroundAdejumo, A., Alliu, S., Ajayi, T. O., Adejumo, K. L., Adegbala, O. M., Onyeakusi, N. E., Akinjero, A., Durojaiye, M., & Bukong, T. N. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176416 · Cited by 86
“Obesity and DM are among the known risk factors for NAFLD [16].”
BackgroundMethodZHOU, Y. J., LI, Y. Y., NIE, Y. Q., HUANG, C. M., & CAO, C. Y. (2012) · Journal of Digestive Diseases · doi:10.1111/j.1751-2980.2011.00571.x · Cited by 78
RetractedPNPLA3 as a therapeutic target for fatty liver disease: the evidence to date
Cherubini, A., Casirati, E., Tomasi, M., & Valenti, L. (2021) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2021.2018418 · Cited by 79
“IL-6 and TNF-α) that promote steatosis and hyperglycemia [1,18].”
BackgroundHashemi, M. M., Bojd, H. H., Eskandari‐Nasab, E., Bahari, A., Hashemzehi, N.-A., Shafieipour, S., Narouie, B., Taheri, M., & Ghavami, S. (2013) · Hepatitis Monthly · doi:10.5812/hepatmon.9527 · Cited by 81
“The prevalence of NAFLD is rising worldwide (5).”
BackgroundInfluentialNoshahr, Z. S., Hadjzadeh, M., Moradi‐Marjaneh, R., & Rad, A. K. (2020) · Food Science & Nutrition · doi:10.1002/fsn3.2090 · Cited by 91
“Nonalcoholic fatty liver disease (NAFLD), including fatty liver, liver fibrosis, and cirrhosis, have been known as common consequences of diabetes (Lankarani et al., 2013; Bellentani et al., 2010).”
BackgroundThe influence of NAFLD on the risk of atherosclerosis and cardiovascular diseases
Wójcik, K., Koślińska-Berkan, E., & Piekarska, A. (2018) · Clinical and Experimental Hepatology · doi:10.5114/ceh.2018.73155 · Cited by 83
“However, experts estimate that NAFLD affects from 25% to 90% of obese patients and 70% of patients with diabetes mellitus [1, 2].”
BackgroundChan, W., Tan, A. T., Vethakkan, S. R., Tah, P., Vijayananthan, A., & Goh, K. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12204 · Cited by 78
Gonçalves, E. M. A. R., Roesler, B. M., & Zeitune, J. M. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i30.2968 · Cited by 87
Gerges, S. H., Wahdan, S. A., Elsherbiny, D. A., & El‐Demerdash, E. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119220 · Cited by 84
Hepatic insulin receptor: new views on the mechanisms of liver disease
Lee, W., Najjar, S. M., Kahn, C. R., & Hinds, T. D. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155607 · Cited by 79
The sedentary (r)evolution: Have we lost our metabolic flexibility?
Freese, J., Klement, R. J., Ruiz-Núñez, B., Schwarz, S., & Lötzerich, H. (2018) · F1000Research · doi:10.12688/f1000research.12724.2 · Cited by 61
“A non-alcoholic fatty liver (NAFL) is present in nearly 25–50% of the general population in Western countries 158,159 and strongly related to T2D, hyperglycemia, hyperinsulinemia, low HDL-cholesterol and represents an independent risk factor for cardio-vascular diseases 160 .”
Sharma, L., Lone, N. A., Knott, R. M., Hassan, A., & Abdullah, S. T. (2018) · Food and Chemical Toxicology · doi:10.1016/j.fct.2018.09.011 · Cited by 80
Impaired Hepatic Vitamin A Metabolism in NAFLD Mice Leading to Vitamin A Accumulation in Hepatocytes
Saeed, A., Bartuzi, P., Heegsma, J., Dekker, D., Kloosterhuis, N., de Bruin, A., Jonker, J. W., van de Sluis, B., & Faber, K. N. (2020) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2020.07.006 · Cited by 83
“NALFD prevalence is particularly high in obese individuals (80%–90%), diabetes (30%–50%), or hyperlipidemia (90%).(1,2) Hepatic fat accumulation is a combined result of a high fat– and high carbohydrate–containing diet and insuffi-”
BackgroundAssociation of Adipose Tissue and Adipokines with Development of Obesity-Induced Liver Cancer
Rajesh, Y., & Sarkar, D. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042163 · Cited by 82
“Consequently, NAFLD and NASH are the most common liver disorders, with up to a 90% prevalence in the obese population [28].”
BackgroundWhat Should We Recommend to Our Patients with NAFLD Regarding Alcohol Use?
Liangpunsakul, S., & Chalasani, N. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.20 · Cited by 73
“Its prevalence has been continuously rising over the past decade in both children and adults (2,3), and it is estimated that 17–35% of US adults may have NAFLD (4).”
BackgroundKim, W., Kim, B. G., Lee, J. S., Lee, C. K., Yeon, J. E., Chang, M. S., Kim, J. H., Kim, H., Yi, S., Lee, J., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13981 · Cited by 75
Cost-utility analysis of nonalcoholic steatohepatitis screening
Zhang, E. W., Wartelle‐Bladou, C., Lepanto, L., Lachaîne, J., Cloutier, G., & Tang, A. (2015) · European Radiology · doi:10.1007/s00330-015-3731-2 · Cited by 83
“It affects an estimated 20– 30 % of the general adult population, and as much as 90 % of diabetic or obese patients [2–4].”
BackgroundNutritional Management of Insulin Resistance in Nonalcoholic Fatty Liver Disease (NAFLD)
Conlon, B., Beasley, J., Aebersold, K., Jhangiani, S., & Wylie-Rosett, J. (2013) · Nutrients · doi:10.3390/nu5104093 · Cited by 72
“More than 30% of morbidly obese patients may have NASH and 12%–25% have fibrosis [17–19].”
BackgroundInfluentialNon-alcohol fatty liver disease in Asia: Prevention and planning
Ashtari, S., Pourhoseingholi, M. A., & Zali, M. R. (2015) · World Journal of Hepatology · doi:10.4254/wjh.v7.i13.1788 · Cited by 84
Mahaling, D. U., Basavaraj, M. M., & Bika, A. J. (2013) · Asian Pacific Journal of Tropical Biomedicine · doi:10.1016/s2221-1691(13)60177-x · Cited by 99
Lipid Disorders and Metabolic-Associated Fatty Liver Disease
Anwar, S. D., Foster, C., & Ashraf, A. P. (2023) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2023.01.003 · Cited by 78
Alcoholic and non-alcoholic steatohepatitis
Neuman, M. G., French, S. W., French, B. A., Seitz, H. K., Cohen, L. B., Mueller, S., Osna, N. A., Kharbanda, K. K., Seth, D., Bautista, A., et al. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.09.005 · Cited by 70
“There have been three large population-based studies to determine the prevalence of NAFLD (Bellentani et al., 2010; Lazo et al., 2013).”
BackgroundNLRPs, microbiota, and gut homeostasis: unravelling the connection
Zambetti, L. P., & Mortellaro, A. (2014) · The Journal of Pathology · doi:10.1002/path.4357 · Cited by 69
“J Pathol 2014; 233: 321–330 Published by John Wiley & Sons, Ltd. www.pathsoc.org.uk www.thejournalofpathology.com (NAFLD) [57] (for a review on this topic, see Bellentani et al [58]).”
BackgroundSustained telomere length in hepatocytes and cholangiocytes with increasing age in normal liver
Verma, S., Tachtatzis, P., Penrhyn-Lowe, S., Scarpini, C., Jurk, D., Von Zglinicki, T., Coleman, N., & Alexander, G. J. M. (2012) · Hepatology · doi:10.1002/hep.25787 · Cited by 72
Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease?
Scalera, A., & Tarantino, G. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i28.9217 · Cited by 76
The Role of Gastrointestinal Hormones in Hepatic Lipid Metabolism
Mells, J., & Anania, F. (2013) · Seminars in Liver Disease · doi:10.1055/s-0033-1358527 · Cited by 70
“5–7 A common feature of MetS-related disease is both hepatic and systemic insulin resistance.”
BackgroundNonalcoholic Fatty Liver Disease
Paredes, A. H., Torres, D. M., & Harrison, S. A. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.03.005 · Cited by 75
Hashemi, S.-A., Alavian, S. M., & Fesharaki, M. G. (2016) · PubMed Central · Cited by 72
Metadata
- Authors
- Bellentani, S., Scaglioni, F., Marino, M., & Bedogni, G.
- Venue
- Digestive Diseases
- Publisher
- S. Karger AG
- Published
- 2010
- Volume
- 28
- Issue
- 1
- Pages
- 155-161
- ISSN
- 0257-2753 (ISSN-L)
- 1421-9875
- OpenAlex
- W2036047239
- Cited by
- 1,026
- References
- 77
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 31 · 2023: 51 · 2022: 72 · 2021: 71 · 2020: 78 · 2019: 85 · 2018: 96 · 2017: 97 · 2016: 89 · 2015: 84 · 2014: 71 · 2013: 81 · 2012: 48
- FWCI
- 40.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Digestive Diseases (publishedVersion)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Pathology and Forensic Medicine › Alcohol Consumption and Health Effects
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- non-alcoholic fatty liver disease, prevalence, nonalcoholic steatohepatitis, liver cirrhosis, hepatocellular carcinoma, risk factors, obesity, insulin resistance, metabolic syndrome, fatty liver index, NAFLD screening, pediatric NAFLD, incidence, lifestyle, transaminases
- MeSH terms
- Adult, Aged, Fatty Liver, Female, Humans, Italy, Male, Middle Aged, Risk Factors, United States, Prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.